PT2912183T - Promotor pr13.5 para respostas robustas de células t e anticorpos - Google Patents

Promotor pr13.5 para respostas robustas de células t e anticorpos

Info

Publication number
PT2912183T
PT2912183T PT137838520T PT13783852T PT2912183T PT 2912183 T PT2912183 T PT 2912183T PT 137838520 T PT137838520 T PT 137838520T PT 13783852 T PT13783852 T PT 13783852T PT 2912183 T PT2912183 T PT 2912183T
Authority
PT
Portugal
Prior art keywords
robust
promoter
cell
antibody responses
responses
Prior art date
Application number
PT137838520T
Other languages
English (en)
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of PT2912183T publication Critical patent/PT2912183T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/863Poxviral vectors, e.g. entomopoxvirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT137838520T 2012-10-28 2013-10-28 Promotor pr13.5 para respostas robustas de células t e anticorpos PT2912183T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261719429P 2012-10-28 2012-10-28

Publications (1)

Publication Number Publication Date
PT2912183T true PT2912183T (pt) 2020-06-05

Family

ID=49513897

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137838520T PT2912183T (pt) 2012-10-28 2013-10-28 Promotor pr13.5 para respostas robustas de células t e anticorpos

Country Status (26)

Country Link
US (2) US9828414B2 (pt)
EP (2) EP3778904A1 (pt)
JP (2) JP6505016B2 (pt)
KR (2) KR20200087880A (pt)
CN (1) CN104755622B (pt)
AU (1) AU2013337018B2 (pt)
BR (1) BR112015009320A2 (pt)
CA (1) CA2887623C (pt)
CY (1) CY1123181T1 (pt)
DK (1) DK2912183T3 (pt)
EA (2) EA201990114A1 (pt)
ES (1) ES2800623T3 (pt)
HK (1) HK1212383A1 (pt)
HU (1) HUE049706T2 (pt)
IL (1) IL238130B (pt)
IN (1) IN2015DN03326A (pt)
LT (1) LT2912183T (pt)
MX (2) MX2015005264A (pt)
MY (2) MY171687A (pt)
NZ (1) NZ706637A (pt)
PT (1) PT2912183T (pt)
SG (2) SG11201503200PA (pt)
SI (1) SI2912183T1 (pt)
UA (1) UA118340C2 (pt)
WO (1) WO2014063832A1 (pt)
ZA (1) ZA201502892B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6505016B2 (ja) * 2012-10-28 2019-04-24 バヴァリアン・ノルディック・アクティーゼルスカブ 強靭なt細胞用のpr13.5プロモータ及び抗体応答
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
AU2017259259B2 (en) * 2016-05-02 2020-11-19 Bavarian Nordic A/S Therapeutic HPV vaccine combinations
RU2756534C2 (ru) 2016-09-28 2021-10-01 Бавариан Нордик А/С Композиции и способы для повышения стабильности трансгенов в поксвирусах
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
DK3562946T3 (da) 2016-12-28 2022-01-31 Transgene Sa Oncolytiske virusser og terapeutiske molekyler
MA49397A (fr) * 2017-06-15 2020-04-22 Bavarian Nordic As Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
KR20200044000A (ko) 2017-08-24 2020-04-28 버베리안 노딕 에이/에스 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법
EP3727446A1 (en) 2017-12-19 2020-10-28 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
GB201807932D0 (en) * 2018-05-16 2018-06-27 Redchenko Irina Compositions and methods for inducing an immune response
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CN110904127A (zh) 2018-09-18 2020-03-24 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
WO2020070303A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
MX2021005560A (es) 2018-11-20 2021-06-23 Bavarian Nordic As Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l).
JP2023503857A (ja) 2019-11-20 2023-02-01 バヴァリアン・ノルディック・アクティーゼルスカブ がんを治療するための腫瘍内及び/または静脈内投与用組み換えmvaウイルス
MX2022015489A (es) 2020-06-10 2023-03-22 Bavarian Nordic As Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
EP4396333A1 (en) 2021-09-03 2024-07-10 Bavarian Nordic A/S Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva)
CA3240596A1 (en) 2021-12-23 2023-06-29 Cigdem ATAY LANGBEIN Therapy for modulating immune response with recombinant mva encoding il-12
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
TW202413636A (zh) 2022-08-18 2024-04-01 法商傳斯堅公司 嵌合痘病毒
WO2024149832A1 (en) 2023-01-12 2024-07-18 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9922361D0 (en) * 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
EE05680B1 (et) 2000-11-23 2013-10-15 Bavarian Nordic A/S Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin
US7527960B2 (en) * 2004-06-25 2009-05-05 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes
JP2008301792A (ja) 2007-06-11 2008-12-18 National Univ Corp Shizuoka Univ 改変ポリヘドリンプロモーター、バクミド変異体及び目的タンパク質の製造方法
WO2010060632A1 (en) 2008-11-27 2010-06-03 Bavarian Nordic A/S Promoters for recombinant viral expression
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
JP6505016B2 (ja) * 2012-10-28 2019-04-24 バヴァリアン・ノルディック・アクティーゼルスカブ 強靭なt細胞用のpr13.5プロモータ及び抗体応答

Also Published As

Publication number Publication date
WO2014063832A1 (en) 2014-05-01
EP2912183B1 (en) 2020-05-06
CY1123181T1 (el) 2021-10-29
ZA201502892B (en) 2020-08-26
SG11201503200PA (en) 2015-05-28
IL238130A0 (en) 2015-05-31
SI2912183T1 (sl) 2020-07-31
AU2013337018A1 (en) 2015-04-30
KR20150079596A (ko) 2015-07-08
US11028130B2 (en) 2021-06-08
ES2800623T3 (es) 2021-01-04
HK1212383A1 (en) 2016-06-10
SG10201704657WA (en) 2017-07-28
JP6505016B2 (ja) 2019-04-24
KR102135818B1 (ko) 2020-07-22
CN104755622B (zh) 2021-04-20
AU2013337018A9 (en) 2018-08-30
LT2912183T (lt) 2020-07-27
EA201990114A1 (ru) 2019-09-30
AU2013337018B2 (en) 2019-09-05
JP2019131572A (ja) 2019-08-08
DK2912183T3 (da) 2020-07-27
US20180111966A1 (en) 2018-04-26
EP2912183A1 (en) 2015-09-02
MX2021001638A (es) 2021-05-12
JP2015533841A (ja) 2015-11-26
KR20200087880A (ko) 2020-07-21
UA118340C2 (uk) 2019-01-10
MX2015005264A (es) 2015-07-17
CA2887623C (en) 2021-02-16
MY194609A (en) 2022-12-06
MY171687A (en) 2019-10-23
EA201590831A1 (ru) 2015-08-31
BR112015009320A2 (pt) 2017-10-17
US9828414B2 (en) 2017-11-28
CN104755622A (zh) 2015-07-01
EA032498B1 (ru) 2019-06-28
US20150299267A1 (en) 2015-10-22
JP6818797B2 (ja) 2021-01-20
CA2887623A1 (en) 2014-05-01
EP3778904A1 (en) 2021-02-17
IN2015DN03326A (pt) 2015-10-09
HUE049706T2 (hu) 2020-10-28
IL238130B (en) 2019-09-26
NZ706637A (en) 2019-02-22

Similar Documents

Publication Publication Date Title
HK1212383A1 (en) Pr13.5 promoter for robust t-cell and antibody responses t pr135
IL256716A (en) Antibodies against hla–b*27 and their uses
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
PT2697187T (pt) Olefinas e métodos para produção das mesmas
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP2861623A4 (en) NEW SPECIFIC CLEC14A ANTIBODY AND USES THEREOF
HK1202296A1 (en) Anti-adamts-5 antibody, derivatives and uses thereof adamts-5
ZA201408213B (en) Anti-transglutaminase 2 antibodies
EP2927243A4 (en) ANTI-VASOHIBIN ANTIBODY-2
GB201208372D0 (en) Antibodies and uses thereof